|
Gabor M. Rubanyi, M.D., Ph.D. is Chief Scientific Officer of Cardium Therapeutics, Inc. Prior to joining Cardium in June 2006, he was Vice President and Head of the Gene Therapy Department at Berlex Biosciences in Richmond, California and Adjunct Professor of Molecular and Cellular Physiology at the University of California at Davis. He initiated and played a leading role in the Angiogenic Gene Therapy for Coronary Artery Disease project at Schering/Berlex. Formerly, he was Director of Vascular and Endothelial Research at Berlex (1992-1999), Director of the Institute of Pharmacology at Schering AG, Research Center, Berlin, Germany (1990-1992), Director of Pharmacology at Berlex Laboratories, Cedar Knolls, New Jersey (1987-1990) and Associate Professor at the Mayo Clinic Medical School, Rochester, Minnesota (1983-1987). The author and co-author of 22 books and over 325 research articles, he serves as an editorial board member for several biomedical journals and is a member of numerous American and international scientific societies. He is the Founder of the biomedical journal Endothelium. His pioneering work on the nature and characterization of endothelium-derived relaxing and contracting factors contributed in a significant way to our present knowledge about endothelial control of vascular function in health and disease.
| 